©2026 Bryn Mawr Communications, LLC.
All Rights Reserved

Terms and Conditions • Privacy Policy

Contributor:

Diabetic Retinopathy Severity and Income Status
Diabetic Retinopathy Severity and Income Status

Ben Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD

Switching from Aflibercept to Faricimab in Wet AMD Patients
Switching from Aflibercept to Faricimab in Wet AMD Patients

Ben Young, MD, MS; Lediana Goduni, MD; and Joshua Uhr, MD

Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab
Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab

Ben Young, MD; Pheobe Mellen, MD; and Jordan Deaner, MD

New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF Therapy
New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF Therapy

Ben Young, MD, MS; Lediana Goduni, MD; and Josh Uhr, MD

Diabetic Retinopathy Severity and Income Status

Ben Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD

Switching from Aflibercept to Faricimab in Wet AMD Patients

Ben Young, MD, MS; Lediana Goduni, MD; and Joshua Uhr, MD,

New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab

Ben Young, MD; Pheobe Mellen, MD; and Jordan Deaner, MD

New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF Therapy

Ben Young, MD, MS; Lediana Goduni, MD; and Josh Uhr, MD,